全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Restless Leg Syndrome Following Aripiprazole Discontinuation: A Case Report

DOI: 10.4236/crcm.2025.143023, PP. 176-181

Keywords: Aripiprazole Withdrawal, Restless Legs Syndrome, Akathisia, Dopamine Dysregulation

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background: Aripiprazole is a second-generation antipsychotic known for its partial dopamine D2 agonist properties, which help reduce the risk of extrapyramidal symptoms. While effective and generally well-tolerated, withdrawal symptoms, such as Restless Legs Syndrome (RLS) and akathisia, have been observed upon abrupt discontinuation in some patients. Objective: To report a rare case of Restless Legs Syndrome (RLS) following the discontinuation of aripiprazole in a patient with a history of substance-induced psychosis. Case Description: A 39-year-old male with a history of polysubstance use in sustained remission, presented with RLS-like symptoms shortly after discontinuing aripiprazole, which he had taken consistently for the last 6 years. The symptoms, which included a pinching sensation in his thighs, involuntary leg movements during sleep, and a sense of restlessness, emerged within 2 - 3 days of medication cessation. These symptoms are resolved within an hour of reinitiating aripiprazole. The patient’s clinical presentation underscores a rare but clinically significant withdrawal phenomenon associated with aripiprazole discontinuation, potentially linked to dopamine dysregulation. Conclusions: This case highlights the importance of recognizing and managing aripiprazole discontinuation symptoms, including RLS. Clinicians should consider a gradual tapering protocol for aripiprazole to minimize withdrawal-related movement disorders and monitor patients for emergent symptoms. Further research is recommended to establish standardized guidelines for managing similar cases.

References

[1]  Stahl, S.M. (2024) Prescriber’s Guide: Antidepressants: Stahl’s Essential Psychopharmacology.
https://books.google.co.uk/books?hl=en&lr=&id=LEY3DwAAQBAJ&oi=fnd&pg=PR7&dq=%5B1%5D+Stahl,+S.+M.+(2017).+Stahl%27s+prescriber%27s+guide+(6th+ed.,+p.+53).+Cambridge+University+Press.&ots=E3BPDrgQj9&sig=lct58kABR77d27za_R2f2NUZUf8#v=onepage&q&f=false
[2]  Sadock, B.J. Sadock, V.A. and Ruiz, P. (2015) Kaplan & Sadock’s Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. Wolters Kluwer.
https://books.google.com/books/about/Kaplan_Sadock_s_Synopsis_of_Psychiatry.html?id=QQmOngEACAAJ
[3]  Gardos, G., Cole, J.O. and Tarsy, D. (1978) Withdrawal Syndromes Associated with Antipsychotic Drugs. American Journal of Psychiatry, 135, 1321-1324.
https://doi.org/10.1176/ajp.135.11.1321
[4]  Trenkwalder, C., Allen, R., Högl, B., Clemens, S., Patton, S., Schormair, B., et al. (2018) Comorbidities, Treatment, and Pathophysiology in Restless Legs Syndrome. The Lancet Neurology, 17, 994-1005.
https://doi.org/10.1016/s1474-4422(18)30311-9
[5]  Moseley, C.N., Simpson-Khanna, H.A., Catalano, G. and Catalano, M.C. (2013) Covert Dyskinesia Associated with Aripiprazole. Clinical Neuropharmacology, 36, 128-130.
https://doi.org/10.1097/wnf.0b013e31829b99d9
[6]  Taylor, D.M., Barnes, T.R.E. and Young, A.H. (2021) The Maudsley Prescribing Guidelines in Psychiatry. 14th Edition, Wiley-Blackwell.
https://doi.org/10.1002/9781119870203
[7]  Stroup, T.S., McEvoy, J.P., Ring, K.D., Hamer, R.H., LaVange, L.M., Swartz, M.S., et al. (2011) A Randomized Trial Examining the Effectiveness of Switching from Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). American Journal of Psychiatry, 168, 947-956.
https://doi.org/10.1176/appi.ajp.2011.10111609
[8]  Shapiro, D.A., Renock, S., Arrington, E., Chiodo, L.A., Liu, L., Sibley, D.R., et al. (2003) Aripiprazole, a Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology. Neuropsychopharmacology, 28, 1400-1411.
https://doi.org/10.1038/sj.npp.1300203
[9]  Shireen, E. (2016) Experimental Treatment of Antipsychotic-Induced Movement Disorders. Journal of Experimental Pharmacology, 8, 1-10.
https://doi.org/10.2147/jep.s63553
[10]  de Bartolomeis, A., Tomasetti, C. and Iasevoli, F. (2015) Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs, 29, 773-799.
https://doi.org/10.1007/s40263-015-0278-3

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133